Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Collaboration With Industry And CMS Are Priorities For FDA’s Gottlieb

This article was originally published in The Gray Sheet

Executive Summary

The pressure of meeting MDUFMA premarket review deadlines has prevented FDA reviewers from having "as much interaction as they would like with companies," according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
Advertisement

Related Content

FDA Premarket Activity Safe From Current Political Storm – Ex Chief Counsel
FDA Premarket Activity Safe From Current Political Storm – Ex Chief Counsel
“Passive” Adverse Event Data Inadequate, Say FDA/HRS Meeting Panelists
Funding Limits Will Force Choices At Device Evaluation Office – Tillman
Funding Limits Will Force Choices At Device Evaluation Office – Tillman
Advertisement
UsernamePublicRestriction

Register

MT022833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel